Research

Hormonal

Chronic administration of GIP receptor agonists (specifically GIP108) causes functional desensitization of the GIP receptor in pancreatic islets, reducing the efficacy of subsequent glucose-lowering challenges.

Long-term use of GIP-based therapies (like tirzepatide) triggers a biological adaptation where the pancreas becomes less responsive to the drug's glucose-lowering signal. This is a known mechanism called desensitization. However, the drug still promotes weight loss, suggesting the benefit comes from multiple pathways, not just pancreatic sensitivity. If glycemic control wanes, dose adjustments may be necessary.

GoodSupportsHIGH confidence
Prolonged exposure to GIPR agonists produced homologous functional GIPR desensitisation in isolated islets. GIP108 pre-treatment in vivo also reduced the subsequent anti-hyperglycaemic response to GIP re-challenge.
Iona Davies et al. · Molecular Metabolism · 2025

Why this rating

High-quality in vivo and ex vivo mechanistic data using specific transgenic mouse models and long-acting agonists, though limited to murine models.

Source

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation

Iona Davies et al. · Molecular Metabolism · 2025

DOI 10.1016/j.molmet.2025.102094

mechanism_onlyCited 13×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →